Our Private Equity Group provides trusted counsel derived from deep industry knowledge to established as well as up-and-coming private equity firms. We represent firms of every size across the spectrum of investment strategies, and we build long-standing relationships with our clients. As active participants in the private equity industry, we are able to advise our clients on the latest innovations, as well as current market practices and trends.
The Column Group to Acquire NGM Biopharmaceuticals
- Client News
- February 26, 2024
Paul, Weiss is advising entities of The Column Group, LP in their take-private acquisition of NGM Biopharmaceuticals, Inc., a biotechnology company focused on transformative therapeutics. Under the terms of the deal, Atlas Neon Parent, Inc. and its affiliate Atlas Neon Merger Sub, Inc., both entities affiliated with The Column Group, will acquire NGM Bio through a cash tender offer for all outstanding shares of the company at a price per share of $1.55. The Column Group, along with other existing stockholders, will contribute their shares to the purchasing entity as part of the transaction rather than receive the cash offer.
The Column Group is NGM Bio’s longest and largest stockholder, holding approximately 26% of its outstanding shares. The acquisition is expected to close in the second quarter of 2024, subject to customary closing conditions.
The Paul, Weiss team is led by corporate partners Austin Pollet and Luke Jennings, and includes executive compensation partner Andrea Wahlquist Brown and counsel Sasha Belinkie and Christopher Gonnella; intellectual property partner Jonathan Ashtor; tax partner Matthew Jordan; litigation counsel Steven Herzog; and antitrust counsel Marta Kelly.